New Issue: Orbital Catastrophe Ahead? Read Now

Painkillers Thwart Prozac

Over-the-counter pain relievers may block some antidepressants

Join Our Community of Science Lovers!

People with depression encounter a lot of pharmaceutical frustration. For largely unknown reasons, roughly one in three patients receive no benefit from any antidepressant. A recent study, however, suggests that something as simple as over-the-counter painkillers could play a role. Ibuprofen, aspirin and other anti-inflammatory drugs may disrupt the action of selective serotonin reuptake inhibitors (SSRIs), the most commonly prescribed type of antidepressant.

Antidepressants alter brain chemistry. SSRIs increase the amount of the neurotransmitter serotonin in the space between brain cells. Neuroscientist Jennifer L. Warner-Schmidt of the Rockefeller University and her colleagues noticed that certain proteins in the brain that interact with SSRIs had the potential to be influenced by anti-inflammatory drugs such as pain relievers.

The team embarked on a series of experiments in rodents to explore this idea. In one test, researchers measured how long it takes a mouse to overcome its fear of a new, open space and move toward food placed in the center. Mice that had been given the SSRI citalopram for two weeks approached the food more than twice as quickly as unmedicated mice. But mice given ibuprofen with the SSRI for two weeks headed for the food nearly as slowly as un­medicated mice, Warner-Schmidt and her colleagues report in the Proceedings of the National Academy of Sciences USA.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


The researchers also examined information from a previous study of patients with treatment-resistant depression. The study evaluated how the participants responded to a 12-week course of citalopram and noted other medication use. Patients who had taken an anti-inflammatory drug or acetaminophen during their SSRI treatment were significantly less likely to experience relief from their symptoms than patients who had not.

The researchers are planning studies to figure out how exactly the pain medications interfere with the SSRIs and to determine how big a dose of painkillers is detrimental. But the evidence so far “is clinically important,” Warner-Schmidt says. “It’s a piece of information that doctors should keep in mind when looking at an individual who is not responding to an SSRI.”

SA Mind Vol 22 Issue 4This article was published with the title “Painkillers Thwart Prozac” in SA Mind Vol. 22 No. 4 (), p. 11
doi:10.1038/scientificamericanmind0911-11b

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe